Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Research & Development (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Research & Development data on record, last reported at $74.2 million in Q4 2025.

  • For Q4 2025, Research & Development fell 2.78% year-over-year to $74.2 million; the TTM value through Dec 2025 reached $295.9 million, down 9.68%, while the annual FY2025 figure was $295.9 million, 9.68% down from the prior year.
  • Research & Development reached $74.2 million in Q4 2025 per APLS's latest filing, up from $68.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $110.0 million in Q1 2023 and bottomed at $67.0 million in Q2 2025.
  • Average Research & Development over 5 years is $85.5 million, with a median of $85.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: skyrocketed 55.32% in 2021, then crashed 30.32% in 2023.
  • A 5-year view of Research & Development shows it stood at $78.2 million in 2021, then rose by 27.17% to $99.4 million in 2022, then tumbled by 30.32% to $69.3 million in 2023, then rose by 10.21% to $76.4 million in 2024, then dropped by 2.78% to $74.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $74.2 million in Q4 2025, $68.2 million in Q3 2025, and $67.0 million in Q2 2025.